How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

466 results for

Pulmonary Hypertension in Sickle Cell Anemia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Stem Cell Gene Therapy for Sickle Cell Disease

or brain MRI demonstrating previous stroke Administration of regular RBC transfusions for equal or longer than 1 year to prevent vaso-occlusive crises or other sickle cell disease complications or to maintain Hb >6. Pulmonary arterial hypertension with tricuspid regurgitant jet velocity > 2.5 m/sec. At least one episode of acute chest syndrome that required hospitalization, intubation, and mechanical ventilation support within the 2 years prior to enrollment At least 2 acute sickle pain crises (...) relevant MeSH terms: Layout table for MeSH terms Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn

2014 Clinical Trials

82. Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

less than 1.5 g/dL Serum ferritin ≥ 100 ng/mL, or TSAT ≥20% during the screening period Folate and vitamin B12 ≥ lower limit of normal during the screening period Exclusion Criteria: Anemia due to a main cause other than CKD: sickle cell disease, myelodysplastic syndrome, bone marrow fibrosis, hematologic malignancy, hemolytic anemia, thalassemia, or pure red cell aplasia Active bleeding or recent blood loss within 8 weeks prior to the screening period RBC transfusion within 8 weeks prior (...) is not an exclusion criterion New onset or recurrent event of deep vein thrombosis or pulmonary embolism within 12 weeks prior to the screening period Current or history of hemosiderosis or hemochromatosis History of prior organ transplantation or scheduled organ transplant, or prior transplantation of hematopoietic stem cell or bone marrow Males and females of childbearing potential who are unwilling to use an acceptable method of contraception during the designated period (Males: during the study and 90 days

2017 Clinical Trials

83. Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

period less than 1.5 g/dL Serum ferritin ≥ 100 ng/mL, or TSAT ≥20% during the screening period Folate and vitamin B12 ≥ lower limit of normal during the screening period Exclusion Criteria: Anemia due to a main cause other than CKD: sickle cell disease, myelodysplastic syndrome, bone marrow fibrosis, hematologic malignancy, hemolytic anemia, thalassemia, or pure red cell aplasia Active bleeding or recent blood loss within 8 weeks prior to the screening period RBC transfusion within 8 weeks prior (...) thrombosis or pulmonary embolism within 12 weeks prior to the screening period Current or history of hemosiderosis or hemochromatosis History of prior organ transplantation or scheduled organ transplant, or prior transplantation of hematopoietic stem cell or bone marrow Males and females of childbearing potential who are unwilling to use an acceptable method of contraception during the designated period (Males: during the study and 90 days after the last dose, females: during study and 30 days after

2017 Clinical Trials

84. A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases

Last Verified: January 2019 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by Gregory J. Kato, MD, University of Pittsburgh: SCD Sickle Cell Disease Riociguat Adempas Additional relevant MeSH terms: Layout table for MeSH terms Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases (...) A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Multi-Center

2015 Clinical Trials

85. Evaluation of a Training Program for Homozygous Sickle Cell Disease Patients

: Layout table for MeSH terms Anemia, Sickle Cell Sickle Cell Trait Hemoglobin C Disease Hemoglobin SC Disease Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn (...) Evaluation of a Training Program for Homozygous Sickle Cell Disease Patients Evaluation of a Training Program for Homozygous Sickle Cell Disease Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2015 Clinical Trials

86. The Role of Endothelin-1 in Sickle Cell Disease

Intervention/treatment Phase Sickle Cell Anemia Drug: Ambrisentan Drug: Placebo Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 30 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment Official Title: The Role of Endothelin-1 in Sickle Cell Disease Study Start Date : September 2015 Estimated Primary Completion Date (...) 2019 Keywords provided by Abdullah Kutlar, Augusta University: Sickle Cell Anemia Sickle Cell Thalassemia Sickle Beta Thalassemia Proteinuria Sickle nephropathy Additional relevant MeSH terms: Layout table for MeSH terms Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn Ambrisentan Antihypertensive Agents

2015 Clinical Trials

87. Genetic diminution of circulating prothrombin ameliorates multi-organ pathologies in sickle cell disease mice. (PubMed)

Genetic diminution of circulating prothrombin ameliorates multi-organ pathologies in sickle cell disease mice. Sickle cell disease (SCD) results in vascular occlusions, chronic hemolytic anemia, and cumulative organ damage. A conspicuous feature of SCD is chronic inflammation and coagulation system activation. Thrombin (factor IIa [FIIa]) is both a central protease in hemostasis and a key modifier of inflammatory processes. To explore the hypothesis that reduced prothrombin (factor II [FII (...) end-organ damage (nephropathy, pulmonary hypertension, pulmonary inflammation, liver function, inflammatory infiltration, and microinfarctions). Notably, all of these benefits were achieved with a relatively modest 1.25-fold increase in prothrombin times, and in the absence of hemorrhagic complications. Taken together, these data establish that prothrombin is a powerful modifier of SCD-induced end-organ damage, and present a novel therapeutic target to ameliorate SCD pathologies. © 2015

Full Text available with Trip Pro

2015 Blood

88. Elevated Transpulmonary Gradient and Cardiac Magnetic Resonance-Derived Right Ventricular Remodeling Predict Poor Outcomes in Sickle Cell Disease. (PubMed)

PHS HHS United States 1ZIAHL006137 PHS HHS United States 1ZIAHL006011 PHS HHS United States 1ZIEHL006139 PHS HHS United States ZIA HL006011 HL NHLBI NIH HHS United States 1ZIAHL006012 PHS HHS United States Clinical Trial Letter Research Support, N.I.H., Extramural 2015 11 20 Italy Haematologica 0417435 0390-6078 IM Adult Anemia, Sickle Cell complications diagnosis mortality pathology Cardiac Catheterization Cardiac Output Cardiac Volume Female Heart Rate Humans Hypertension, Pulmonary (...) complications diagnosis mortality pathology Magnetic Resonance Imaging Male Middle Aged Survival Analysis Vascular Resistance Ventricular Function, Right Ventricular Remodeling cardiomyopathy magnetic resonance imaging pulmonary hypertension right ventricle sickle cell disease 2015 11 22 6 0 2015 11 22 6 0 2017 1 5 6 0 ppublish 26589907 haematol.2015.125229 10.3324/haematol.2015.125229 PMC4938326 J Magn Reson Imaging. 2007 Sep;26(3):564-8 17729345 Circulation. 2011 Sep 27;124(13):1452-60 21900080 J

Full Text available with Trip Pro

2015 Haematologica

89. Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease

tracking, arterial pulmonary hypertension, left ventricular hypertrophy. Other: Biological parameters Hemoglobin levels, red cells, hematocrit, iron, ferritin Other: Clinical parameters Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness Healthy patients This is the control group for the sickle cell disease patients: each sickle cell disease patient will be matched with a healthy patient of the same sex and of similar age. Other: Cardiac echography (...) anemia, the haemosiderosis risk or, less frequently, to coronary vaso-occlusive damages. The hypervolemia in patients with sickle cell disease causes an overestimation of the ejected left ventricular fraction measured by echocardiography, this parameter being very dependent of the blood volume.It has already been shown that the left ventricular ejection fraction was normal in most patients with sickle cell disease, but that its evaluation by parameters independent from the blood volume showed

2015 Clinical Trials

90. Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease

: Children's Hospital Medical Center, Cincinnati ClinicalTrials.gov Identifier: Other Study ID Numbers: 2012-4851 First Posted: April 8, 2015 Last Update Posted: December 5, 2017 Last Verified: December 2017 Keywords provided by Children's Hospital Medical Center, Cincinnati: Sickle Cell Disease (SCD) Cardiac Magnetic Resonance Imaging (CMR) Cardiomyopathy Pulmonary Hypertension Additional relevant MeSH terms: Layout table for MeSH terms Cardiomyopathies Anemia, Sickle Cell Cardiomyopathy, Restrictive (...) : A, 6 - 13.9 years; B, 14 - 20.9 years; C, 21 years and older; and D, 6 years and older. Criteria Inclusion Criteria: Sickle cell anemia (HbSS) or sickle-β°-thalassemia (HbSβ°) confirmed by hemoglobin separation and identification techniques Ability to cooperate with and undergo CMR without sedation or anesthesia. Ability to cooperate with and undergo echocardiogram Written informed consent in accordance with the institutional policies and federal guidelines must be provided by the participant

2014 Clinical Trials

91. Allograft for Sickle Cell Disease and Thalassemia

and +100 the chimeric status of patients will be assessed by microsatellite analysis of the peripheral blood. More frequent monitoring may be required. Sickle cell patients with pulmonary hypertension will meet with a Pulmonary Medicine Consult to determine appropriate management prior to SCT. Patients with fever or suspected minor infection should await resolution of symptoms before starting the conditioning regimen. Iron chelation must be discontinued > 48 hours before initiating the conditioning (...) that is accompanied by an infarct on cerebral MRI OR an abnormal trans-cranial Doppler examination (≥200m/s); OR B. Sickle cell related renal insufficiency defined by a creatinine level ≥1.5 times the upper limit of normal and kidney biopsy consistent with sickle cell nephropathy OR nephrotic syndrome OR creatinine clearance < 50mL/min OR requiring peritoneal or hemodialysis. OR C. Pulmonary hypertension as defined by tricuspid regurgitant jet velocity (TRV) of ≥ 2.5m/s at least 3 weeks after a vaso-occlusive

2014 Clinical Trials

92. Gene Transfer for Patients With Sickle Cell Disease

Collaborator: Doris Duke Charitable Foundation Information provided by (Responsible Party): Children's Hospital Medical Center, Cincinnati Study Details Study Description Go to Brief Summary: The purpose of this study is to determine whether transfer of a fetal hemoglobin gene using a lentivirus vector (gene transfer) into human blood making cells is safe and feasible in patients with sickle cell disease. Condition or disease Intervention/treatment Phase Sickle Cell Disease Sickle Cell Anemia Genetic: Gene (...) function tests that show severe obstruction, restriction or diffusion defects Patients who are on chronic transfusions for: clinical stroke Pregnant or breast-feeding Alpha thalassemia Cirrhosis of liver, bridging hepatic fibrosis, or active hepatitis Patients with matched sibling donors who have not declined the option of a hematopoietic stem cell transplant Confirmed pulmonary hypertension Any condition which in the opinion of the investigator makes participation ill advised Contacts and Locations Go

2014 Clinical Trials

93. A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease

Numbers: HGB-205 2012-000695-42 ( EudraCT Number ) First Posted: May 30, 2014 Last Update Posted: January 31, 2019 Last Verified: January 2019 Additional relevant MeSH terms: Layout table for MeSH terms Anemia, Sickle Cell Thalassemia beta-Thalassemia Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn (...) A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2014 Clinical Trials

94. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease

in CKD 292 Chapter 3: Use of ESAs and other agents to treat anemia in CKD 299 Chapter 4: Red cell transfusion to treat anemia in CKD 311 Methods for Guideline Development 317 Biographic and Disclosure Information 324 Acknowledgments 330 References 331 http://www.kidney-international.org contents & 2012 KDIGO VOL 2|ISSUE 4|AUGUST (2) 2012TABLES Table 1. Hb levels in children between 1–19 years for initiation of anemia workup 289 Table 2. Hb levels in children between birth and 24 months for initiation (...) of the anemia (Not Graded): K Complete blood count (CBC), which should include Hb concentration, red cell indices, white blood cell count and differential, and platelet count K Absolute reticulocyte count K Serum ferritin level K Serum transferrin saturation (TSAT) K Serum vitamin B 12 and folate levels Chapter 2: Use of iron to treat anemia in CKD TREATMENT WITH IRON AGENTS 2.1.1: When prescribing iron therapy, balance the potential bene?ts of avoiding or minimizing blood transfusions, ESA therapy

2012 National Kidney Foundation

95. Pediatrics, Sickle Cell Disease (Follow-up)

hemolytic markers, iron overload, and a history of priapism. Even modestly increased pulmonary artery pressures are associated with severe reduction in exercise capacity, as assessed by both the 6-minute walk and cardiopulmonary exercise testing, and herald a poor prognosis. Both pulmonary hypertension and cardiac sequelae, such as diastolic dysfunction, have been associated with accelerated mortality in the sickle cell disease population. For symptomatic patients, hydroxyurea and chronic transfusion (...) , Summers RM, Gladwin MT, et al. CT and image processing non-invasive indicators of sickle cell secondary pulmonary hypertension. Conf Proc IEEE Eng Med Biol Soc . 2008. 2008:859-62. . . Olujohungbe A, Howard J. The clinical care of adult patients

2014 eMedicine Emergency Medicine

96. Pediatrics, Sickle Cell Disease (Diagnosis)

(ABPM) to identify these conditions in young patients. [ ] In the study, 17 patients (43.6%) had ambulatory hypertension, whereas 4 (10.3%) had hypertension on the basis of their clinic blood pressure. Twenty-three patients (59%) had impaired systolic blood pressure dipping, 7 (18%) had impaired diastolic blood pressure dipping, and 5 (13%) had reversed dipping. [ ] Imaging studies Imaging studies that aid in the diagnosis of sickle cell anemia in patients in whom the disease is suggested clinically (...) In the United States, approximately 100,000 people have SCD SCD occurs in about 1 of every 16,300 Hispanic-American births Approximately 1 in 13 black or African Americans has sickle cell trait In the United States, SCD accounts for less than 1% of all new cases of end-stage renal disease (ESRD). [ ] The following factors are known to portend a greater likelihood of progression to overt renal failure: hypertension, nephrotic-range proteinuria, hematuria, severe anemia, and a Central African Republic

2014 eMedicine Emergency Medicine

97. Pediatrics, Sickle Cell Disease (Treatment)

hemolytic markers, iron overload, and a history of priapism. Even modestly increased pulmonary artery pressures are associated with severe reduction in exercise capacity, as assessed by both the 6-minute walk and cardiopulmonary exercise testing, and herald a poor prognosis. Both pulmonary hypertension and cardiac sequelae, such as diastolic dysfunction, have been associated with accelerated mortality in the sickle cell disease population. For symptomatic patients, hydroxyurea and chronic transfusion (...) , Summers RM, Gladwin MT, et al. CT and image processing non-invasive indicators of sickle cell secondary pulmonary hypertension. Conf Proc IEEE Eng Med Biol Soc . 2008. 2008:859-62. . . Olujohungbe A, Howard J. The clinical care of adult patients

2014 eMedicine Emergency Medicine

98. Pediatrics, Sickle Cell Disease (Overview)

(ABPM) to identify these conditions in young patients. [ ] In the study, 17 patients (43.6%) had ambulatory hypertension, whereas 4 (10.3%) had hypertension on the basis of their clinic blood pressure. Twenty-three patients (59%) had impaired systolic blood pressure dipping, 7 (18%) had impaired diastolic blood pressure dipping, and 5 (13%) had reversed dipping. [ ] Imaging studies Imaging studies that aid in the diagnosis of sickle cell anemia in patients in whom the disease is suggested clinically (...) In the United States, approximately 100,000 people have SCD SCD occurs in about 1 of every 16,300 Hispanic-American births Approximately 1 in 13 black or African Americans has sickle cell trait In the United States, SCD accounts for less than 1% of all new cases of end-stage renal disease (ESRD). [ ] The following factors are known to portend a greater likelihood of progression to overt renal failure: hypertension, nephrotic-range proteinuria, hematuria, severe anemia, and a Central African Republic

2014 eMedicine Emergency Medicine

99. Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

(TSAT) (screening only): <=20%. Aplasias: History of bone marrow aplasia or pure red cell aplasia. Other causes of anemia: Untreated Pernicious anemia, thalassemia major, sickle cell disease or myelodysplastic syndrome. Gastrointestinal (GI) bleeding: Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease or clinically significant GI bleeding <=4 weeks prior to screening through to randomization (Day 1). MI or acute coronary syndrome: <=4 weeks prior to screening through (...) Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have

2016 Clinical Trials

100. Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

-unrelated kidney transplant within 52 weeks after study start (Day 1). Ferritin: <=100 nanograms (ng)/milliliter (mL) (<=100 micrograms/liter [L]) at screening. Transferrin saturation (TSAT) (screening only): <=20%. Aplasias: History of bone marrow aplasia or pure red cell aplasia. Other causes of anemia: untreated pernicious anemia, thalassemia major, sickle cell disease or myelodysplastic syndrome. Gastrointestinal (GI) bleeding: Evidence of actively bleeding gastric, duodenal, or esophageal ulcer (...) Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>